Year |
Citation |
Score |
2023 |
Lade DM, Agazie YM. Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes. Acs Bio & Med Chem Au. 3: 418-428. PMID 37876496 DOI: 10.1021/acsbiomedchemau.3c00024 |
0.556 |
|
2022 |
Lade DM, Nicoletti R, Mersch J, Agazie YM. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects. European Journal of Medicinal Chemistry. 247: 115017. PMID 36584630 DOI: 10.1016/j.ejmech.2022.115017 |
0.499 |
|
2021 |
Martin E, Agazie YM. SHP2 potentiates the oncogenic activity of beta-catenin to promote triple-negative breast cancer. Molecular Cancer Research : McR. PMID 34389690 DOI: 10.1158/1541-7786.MCR-21-0060 |
0.368 |
|
2020 |
Hartman Z, Geldenhuys WJ, Agazie YM. Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects. Acs Omega. 5: 25113-25124. PMID 33043190 DOI: 10.1021/acsomega.0c02746 |
0.788 |
|
2020 |
Hartman Z, Geldenhuys WJ, Agazie YM. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). The Journal of Biological Chemistry. PMID 32024694 DOI: 10.1074/Jbc.Ra119.011422 |
0.762 |
|
2020 |
Agazie Y, Hartman Z. Abstract P3-10-20: Targeting the tyrosine phosphatase SHP2 is efficacious against HER2-positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-10-20 |
0.807 |
|
2019 |
Agazie Y, Hartman Z. Abstract P6-20-17: Targeting SHP2 for the treatment of HER2-positive breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-20-17 |
0.787 |
|
2018 |
Zhao H, Martin E, Matalkah F, Shah N, Ivanov A, Ruppert JM, Lockman PR, Agazie YM. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene. PMID 30467378 DOI: 10.1038/S41388-018-0574-8 |
0.569 |
|
2016 |
Matalkah F, Martin E, Zhao H, Agazie YM. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Research : Bcr. 18: 2. PMID 26728598 DOI: 10.1186/S13058-015-0659-Z |
0.596 |
|
2015 |
Zhao H, Agazie YM. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. Bmc Cancer. 15: 109. PMID 25885600 DOI: 10.1186/S12885-015-1131-2 |
0.591 |
|
2015 |
Farrugia MK, Sharma SB, Lin CC, McLaughlin SL, Vanderbilt DB, Ammer AG, Salkeni MA, Stoilov P, Agazie YM, Creighton CJ, Ruppert JM. Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. Cell Death & Disease. 6: e1699. PMID 25789974 DOI: 10.1038/cddis.2015.65 |
0.497 |
|
2014 |
Zhao H, Agazie YM. Abstract 2014: SHP2 stabilizes EGFR and beta-catenin to promote the transformation and tumorigenic potential of basal-like and triple-negative breast cancer cells Cancer Research. 74: 2014-2014. DOI: 10.1158/1538-7445.Am2014-2014 |
0.578 |
|
2013 |
Hartman ZR, Schaller MD, Agazie YM. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Molecular Cancer Research : McR. 11: 651-64. PMID 23512980 DOI: 10.1158/1541-7786.Mcr-12-0578 |
0.784 |
|
2013 |
Matalka F, Zhao H, Agazie YM. Abstract LB-280: Inhibition of SHP2 in basal-like and triple-negative breast cancer cells induces basal-to-luminal transition, suppresses tumorigenesis, and blocks metastasis. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-280 |
0.604 |
|
2012 |
Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 32: 4169-80. PMID 23027125 DOI: 10.1038/Onc.2012.418 |
0.783 |
|
2012 |
Zhou X, Agazie YM. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Cellular Signalling. 24: 140-50. PMID 21911055 DOI: 10.1016/J.Cellsig.2011.08.015 |
0.557 |
|
2011 |
Matalka F, Hartman Z, Agazie YM. Abstract 238: Inhibition of SHP2 abolishes mammary tumorigenesis in mice Cancer Research. 71: 238-238. DOI: 10.1158/1538-7445.Am2011-238 |
0.797 |
|
2011 |
Matalka F, Agazie Y. Abstract B69: SHP2 as a novel therapeutic target for triple-negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-B69 |
0.655 |
|
2011 |
Agazie Y, Matalka F, Hartman Z. P3-01-15: The Role of Src Homology Phosphotyrosyl Phosphatase-2 in Basal-Type/Triple-Negative Breast Cancer – Implications for Targeted Therapy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-01-15 |
0.814 |
|
2011 |
Hartman Z, Agazie Y. P2-02-05: Molecular Mechanism for Src Homology Phosphotyrosyl Phosphatase 2 Regulation of Cell Motility and Migration. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-02-05 |
0.804 |
|
2010 |
Zhou X, Ahmed N, Agazie YM. Abstract 3121: A novel molecular mechanism for HER2-induced sustained signaling and transformation Cancer Research. 70: 3121-3121. DOI: 10.1158/1538-7445.Am10-3121 |
0.555 |
|
2009 |
Zhou X, Agazie YM. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. The Journal of Biological Chemistry. 284: 12226-34. PMID 19261604 DOI: 10.1074/Jbc.M900020200 |
0.57 |
|
2008 |
Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology. 53: 389-402. PMID 18643929 DOI: 10.1111/J.1365-2559.2008.03103.X |
0.484 |
|
2008 |
Zhou XD, Agazie YM. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death and Differentiation. 15: 988-96. PMID 18421299 DOI: 10.1038/cdd.2008.54 |
0.589 |
|
2006 |
Burks J, Agazie YM. Modulation of α-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3 Oncogene. 25: 7166-7179. PMID 16767162 DOI: 10.1038/Sj.Onc.1209728 |
0.485 |
|
2006 |
Merritt R, Hayman MJ, Agazie YM. Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant. Biochimica Et Biophysica Acta. 1763: 45-56. PMID 16413071 DOI: 10.1016/J.Bbamcr.2005.11.013 |
0.373 |
|
2003 |
Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Molecular and Cellular Biology. 23: 7875-86. PMID 14560030 DOI: 10.1128/Mcb.23.21.7875-7886.2003 |
0.375 |
|
2003 |
Agazie YM, Movilla N, Ischenko I, Hayman MJ. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene. 22: 6909-18. PMID 14534538 DOI: 10.1038/Sj.Onc.1206798 |
0.387 |
|
2003 |
Agazie YM, Hayman MJ. Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. The Journal of Biological Chemistry. 278: 13952-8. PMID 12582165 DOI: 10.1074/Jbc.M210670200 |
0.35 |
|
2002 |
Agazie Y, Ischenko I, Hayman M. Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene Oncogene. 21: 697-707. PMID 11850798 DOI: 10.1038/Sj.Onc.1205115 |
0.306 |
|
1998 |
Wilden PA, Agazie YM, Kaufman R, Halenda SP. ATP-stimulated smooth muscle cell proliferation requires independent ERK and PI3K signaling pathways. American Journal of Physiology. Heart and Circulatory Physiology. 275: H1209-H1215. PMID 29586809 DOI: 10.1152/ajpheart.1998.275.4.H1209 |
0.368 |
|
1996 |
Agazie YM, Burkholder GD, Lee JS. Triplex DNA in the nucleus: Direct binding of triplex-specific antibodies and their effect on transcription, replication and cell growth Biochemical Journal. 316: 461-466. PMID 8687388 DOI: 10.1042/Bj3160461 |
0.584 |
|
1995 |
Latimer LJ, Agazie YM, Braun RP, Hampel KJ, Lee JS. Specificity of monoclonal antibodies produced against phosphorothioate and ribo modified DNAs. Molecular Immunology. 32: 1057-64. PMID 8544855 DOI: 10.1016/0161-5890(95)00086-0 |
0.683 |
|
Low-probability matches (unlikely to be authored by this person) |
1998 |
Farah S, Agazie Y, Ohan N, Ngsee JK, Liu XJ. A rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin signaling. The Journal of Biological Chemistry. 273: 4740-6. PMID 9468537 DOI: 10.1074/jbc.273.8.4740 |
0.273 |
|
1998 |
Zhu L, Ohan N, Agazie Y, Cummings C, Farah S, Liu XJ. Molecular cloning and characterization of Xenopus insulin-like growth factor-1 receptor: its role in mediating insulin-induced Xenopus oocyte maturation and expression during embryogenesis. Endocrinology. 139: 949-54. PMID 9492024 DOI: 10.1210/endo.139.3.5824 |
0.223 |
|
2001 |
Agazie YM, Bagot JC, Trickey E, Halenda SP, Wilden PA. Molecular mechanisms of ATP and insulin synergistic stimulation of coronary artery smooth muscle growth. American Journal of Physiology. Heart and Circulatory Physiology. 280: H795-801. PMID 11158979 DOI: 10.1152/AJPHEART.2001.280.2.H795 |
0.155 |
|
Hide low-probability matches. |